Saturday, February 22, 2025 | 10:04 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Divi's Labs gains as USFDA closes out warning letter for Vizag unit

Thus far in the current month, Divi's Labs outperformed the market by gaining 23% after the company on November 2, said that the USFDA will lift import alert for its Visakhapatnam unit.

Divi's Laboratories plant
Premium

Divi's Laboratories plant

SI Reporter Mumbai
Divi’s Laboratories rallied 8% to Rs 1,090 on the BSE in early morning deal after the pharmaceutical company said that the US health regulator has completed evaluation of company’s corrective actions in response to FDA’s warning letter dated April 13.

“Further to our letter dated 2nd November, 2017, Divi's Laboratories  has been informed by the U.S. Food and Drug Administration (US-FDA) that the Agency has completed evaluation of the Company's corrective actions in response to FDA's Warning Letter: 320-17-34 dated April 13, 2017,” the company said in a regulatory filing.

We also note from the update on FDA's

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in